{"ticker": {"uuid": "6d6e93de-74e7-4867-9dbf-c398d509205c", "symbol": "CRNX", "name": "Crinetics Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal", "summary": "Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals (CRNX) for $85 per share in an all-cash deal, valuing the acquisition at approximately $10 billion. The boards of both companies have unanimously approved the transaction, which is expected to close in Q3 of t", "url": "https://finance.yahoo.com/healthcare/articles/vertex-acquire-crinetics-pharmaceuticals-crnx-140143137.html", "source_name": "Market source", "published_at": "2026-07-15T21:01:00", "published_display": "15 Jul 2026 21:01", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex (VRTX) Is Buying Crinetics For $10 Billion To Enter Adrenal Disease", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T12:51:43+00:00", "published_display": "15 Jul 2026 12:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T10:59:35+00:00", "published_display": "15 Jul 2026 10:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals Acquired by Fortress Biotech for $10 Billion", "summary": "Fortress Biotech has acquired Crinetics Pharmaceuticals for approximately $10 billion, significantly enhancing its presence in the rare endocrine disease market. Crinetics' stock surged 99% on the news, despite facing profitability challenges and insider selling activity. The acq", "url": "https://news.biobuzz.io/news/crinetics-pharmaceuticals-acquired-by-fortress-biotech-for-10-billion/", "source_name": "BioBuzz", "published_at": "2026-07-15T03:40:34", "published_display": "15 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals stock hits all-time high at 83.77 USD", "summary": "Crinetics Pharmaceuticals Inc. (CRNX) stock has reached an all-time high of $83.77, reflecting a remarkable 163.21% increase over the past year. The company's market capitalization is now $8.83 billion, though InvestingPro analysis indicates it may be overvalued. This surge in st", "url": "https://www.investing.com/news/company-news/crinetics-pharmaceuticals-stock-hits-alltime-high-at-8377-usd-93CH-4791471", "source_name": "Investing.com", "published_at": "2026-07-14T18:18:52", "published_display": "14 Jul 2026 18:18", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals", "summary": "", "url": "https://finance.yahoo.com/m/26d3cf91-6ce0-39b4-a1c4-3cd3a89b796a/here%27s-why-vertex-was-willing.html", "source_name": "Motley Fool", "published_at": "2026-07-14T12:20:00+00:00", "published_display": "14 Jul 2026 12:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?", "summary": "", "url": "https://finance.yahoo.com/m/a6f71bfb-1081-3188-ab30-14417588df8b/does-vertex%27s-acquisition-of.html", "source_name": "Motley Fool", "published_at": "2026-07-13T18:47:07+00:00", "published_display": "13 Jul 2026 18:47", "sentiment": "positive", "sentiment_pct": 58, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist raises Vertex stock price target to $560 on Crinetics deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQakNJN1VzcnpMTjZnMjZpSWhwSlZibjZhbFZDLWpLTjBJdE5Jd01iVTkxdWQxRkhsejBqeU45QWZpWmpCQXVqcjluV0RjVlU0SVN0cl9wR2xVUVJQMXNkRDNzNkU2Yl9yX0dBaXROVWI4V012bkdXOEJtVVVtU1VRS0t5a3p2dHFBZllXcVJEbFo5LUtnVVNCTzZnZUhWTVNiak1RaVNyendzdXFLdTJzckVkYUZHdDh2Y1Faa21MdFNCbzltU1ZCdU02X1pRYnMySGpR?oc=5", "source_name": "Investing.com UK", "published_at": "2026-07-13T16:22:28+00:00", "published_display": "13 Jul 2026 16:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse", "summary": "", "url": "https://finance.yahoo.com/m/c948983b-0af9-31f4-9c90-8fb379aed97e/vertex-pharmaceuticals-bets.html", "source_name": "MarketBeat", "published_at": "2026-07-11T21:02:09+00:00", "published_display": "11 Jul 2026 21:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Crinetics Pharmaceuticals Inc. (CRNX) Affects Rotational Strategy Timing", "summary": "This article analyzes Crinetics Pharmaceuticals Inc. (CRNX) and its impact on rotational trading strategies, highlighting strong sentiment across all horizons. It provides AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-ti", "url": "https://news.stocktradersdaily.com/news_release/1/How_Crinetics_Pharmaceuticals_Inc._CRNX_Affects_Rotational_Strategy_Timing_071126021202_1783750322.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T02:12:00", "published_display": "11 Jul 2026 02:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals (CRNX) sets 1-year executive non-competes tied to Vertex deal", "summary": "Crinetics Pharmaceuticals has established one-year non-compete agreements with four key executives in connection with its upcoming merger with Vertex Pharmaceuticals. These agreements, effective post-merger, restrict the executives from working for competing businesses in Crineti", "url": "https://www.stocktitan.net/sec-filings/CRNX/8-k-crinetics-pharmaceuticals-inc-reports-material-event-338f33791120.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:09:14", "published_display": "10 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Vertex to Acquire Crinetics Pharmaceuticals", "summary": "Vertex Pharmaceuticals has announced its intention to acquire Crinetics Pharmaceuticals for approximately $4.8 billion. This acquisition will expand Vertex's pipeline, particularly with Crinetics' lead drug candidate, paltusotine, a somatostatin receptor type 2 (SST2) agonist for", "url": "https://www.moomoo.com/news/post/72542735/press-release-vertex-to-acquire-crinetics-pharmaceuticals", "source_name": "Moomoo", "published_at": "2026-07-10T04:10:22", "published_display": "10 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)", "summary": "Monteverde & Associates PC, a class action firm, has launched an investigation into Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) following its proposed acquisition by Vertex Pharmaceuticals Incorporated. The firm is examining whether the offered price of $85.00 per share in cas", "url": "https://www.prnewswire.com/news-releases/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-crinetics-pharmaceuticals-inc-nasdaq-crnx-302822146.html", "source_name": "PR Newswire", "published_at": "2026-07-10T02:09:14", "published_display": "10 Jul 2026 02:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Crinetics Pharmaceuticals Inc \u2013 DUS:6Z4", "summary": "This article from TradingView provides financial information for Crinetics Pharmaceuticals Inc (DUS:6Z4), specifically focusing on its price-to-book forward ratio. The content is primarily a listing of navigation and data sourcing information, indicating that detailed financial m", "url": "https://www.tradingview.com/symbols/DUS-6Z4/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T01:40:40", "published_display": "10 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Crinetics Stock Soared 99% This Week", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQRkJDNWFKa2JZdWRzTTY3bnNkYnRMLUdRUk5fdzJsQWktVjdhYUtwTUtTUHBaemVITlExMGJhOFBJdm84N2FHUW1NM2kyYktVLUR1UGZsNEc3c2FyZmRTaG9PNmVwY3pCYWM5RDQwcTEzSWZ1UmwycFZRbl85SnlZOUVxVDQxYUIzb090ZnV2YW5CdGtfSm9yQXhR?oc=5", "source_name": "Market source", "published_at": "2026-07-09T17:29:39+00:00", "published_display": "09 Jul 2026 17:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's How Much $1000 Invested In Crinetics Pharmaceuticals 5 Years Ago Would Be Worth Today", "summary": "Crinetics Pharmaceuticals (NASDAQ: CRNX) has significantly outperformed the market over the last five years, with an average annual return of 33.07%. A $1000 investment in CRNX stock five years ago would now be worth $4,029.44, demonstrating the substantial impact of compounded r", "url": "https://www.benzinga.com/news/26/07/60345730/here-s-how-much-1000-invested-crinetics-pharmaceuticals-5-years-ago-would-be-worth-today", "source_name": "Benzinga", "published_at": "2026-07-09T08:12:41", "published_display": "09 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex\u2019s Crinetics Deal Balances Growth with Integration Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQRFZNNjhfd3JXNzVPR0xJc2pqby13OTQ5Z1ktWms2YTJiaXNsdjNyUWkyaHVKcmFLbEZxUjh5OGNOZFRoLThxS2ZfWWp5c1B3YjFERGVRZUxkTkQweWJDTkxlMS15Y1FpcElpOXN5ZWRlVF8taFVBT3hRano2U1RYaGpsdlVJTnl2S1VrOTB3VGZNWmVvNXVpeGhmN2t6UQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-08T15:20:35+00:00", "published_display": "08 Jul 2026 15:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Crinetics Pharmaceuticals, Inc. (CRNX) Stock a Buying Opportunity After a 44% Pullback?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQWkJDMVF5SG13QURhc1dlWkJsR2c1c204ZFc0V21QRVlPSWJvQ2ZEOWhKSkZ6YjJ2SmVFUlBvQXMwcXdLQXQwaDctOXBXQm4xcDRpd0F3TVpvb2FQdkR6Y2Rna2lwS05mT1YzcXZvRU5Yd3UwR0tRbTVBSHdpdDFJQ1hEYW14aW5oYzBCcVF5a3VqTzJlemJMOEUyS3RfeFltdm1R?oc=5", "source_name": "Market source", "published_at": "2026-07-08T15:04:40+00:00", "published_display": "08 Jul 2026 15:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal", "summary": "Following Vertex Pharmaceuticals' $10 billion acquisition of Crinetics Pharmaceuticals, Viking Therapeutics (VKTX) has become a subject of renewed takeover speculation, particularly given its advancing obesity and metabolic disorder drug pipeline. The company's VK2735, in late-st", "url": "https://finance.yahoo.com/healthcare/articles/viking-therapeutics-vktx-draws-takeover-091235821.html", "source_name": "Market source", "published_at": "2026-07-08T05:12:00", "published_display": "08 Jul 2026 05:12", "sentiment": "positive", "sentiment_pct": 86, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly price target boost, Vertex-Crinetics deal, Meta's new social media lawsuit", "summary": "JPMorgan raised its price target for Eli Lilly (LLY) due to strong demand for Mounjaro and Zepbound, expecting over $20 billion in sales for the quarter. Vertex Pharmaceuticals (VRTX) is acquiring Crinetics (CRNX) for approximately $10 billion, a move that will likely expand Vert", "url": "https://finance.yahoo.com/video/eli-lilly-price-target-boost-vertex-crinetics-deal-metas-new-social-media-lawsuit-192844891.html", "source_name": "Market source", "published_at": "2026-07-07T19:13:53", "published_display": "07 Jul 2026 19:13", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals (CRNX) Agreed To A $10 Billion All Cash Sale To Vertex", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T16:40:26+00:00", "published_display": "07 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals Stock (CRNX) Opinions on Vertex Acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQZnZPRzNITk1wTEdHSFNUMVk5clU0VjdiemhZbVF3RTVBN3VzZW9PVmRyWlVsT3lBTHpZOTJGaE83bXdQR3pYU2FNM09TeGNhSjUteFUwcVlBVjNCa2RnNXduYm5lYXVvVUtySmlWeTh0V2FMRlJfdWF4aTNQVjYzREtZUGhfTE1oV01EazRMcWVjVm9VeHY0YmdxZDBnMmNMTkVkOHpoYW5VUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-07T14:06:00+00:00", "published_display": "07 Jul 2026 14:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex to Acquire Crinetics in $10 Billion Merger", "summary": "Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion in cash, or $85 per share. This acquisition, expected to close in Q3 2026, will integrate Crinetics' PALSONIFY acromegaly franchise and atumelnant CAH program into Vertex's portfolio, aiming fo", "url": "https://www.tipranks.com/news/company-announcements/vertex-to-acquire-crinetics-in-10-billion-merger", "source_name": "TipRanks", "published_at": "2026-07-07T14:12:41", "published_display": "07 Jul 2026 14:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex to Acquire Crinetics Pharmaceuticals", "summary": "Vertex Pharmaceuticals announced its intent to acquire Crinetics Pharmaceuticals for approximately $10.0 billion, or $8.8 billion net of cash acquired, at $85.00 per share in cash. The acquisition will add Crinetics' recently launched PALSONIFY\u00ae for acromegaly and its Phase 3 can", "url": "https://www.biospace.com/press-releases/vertex-to-acquire-crinetics-pharmaceuticals", "source_name": "BioSpace", "published_at": "2026-07-07T13:40:40", "published_display": "07 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 87, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know (NASDAQ:CRNX)", "summary": "Vertex Pharmaceuticals announced its intention to acquire Crinetics Pharmaceuticals for approximately $10 billion, paying $85 per share. This acquisition aims to diversify Vertex's portfolio beyond cystic fibrosis, adding Crinetics' newly approved acromegaly therapy PALSONIFY and", "url": "https://seekingalpha.com/article/4920310-vertex-to-acquire-crinetics-for-10bn-what-investors-should-know", "source_name": "Seeking Alpha", "published_at": "2026-07-07T13:13:53", "published_display": "07 Jul 2026 13:13", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex to acquire Crinetics in $10B foray into endocrine disease drugs", "summary": "Vertex Pharmaceuticals announced its largest acquisition to date, planning to buy Crinetics Pharmaceuticals for $10 billion (or $85 per share) to expand into endocrine disorder treatments. This strategic move aims to diversify Vertex's portfolio beyond its successful cystic fibro", "url": "https://www.biopharmadive.com/news/vertex-crinetics-acquire-deal-palsonify-acromegaly/824545/", "source_name": "BioPharma Dive", "published_at": "2026-07-07T13:13:53", "published_display": "07 Jul 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex signs agreement to acquire Crinetics for $10bn", "summary": "Vertex Pharmaceuticals has signed a definitive agreement to acquire Crinetics Pharmaceuticals for nearly $10 billion. This acquisition, expected to close in Q3 2026, will add two main endocrinology assets to Vertex's portfolio: Palsonify for acromegaly and atumelnant for congenit", "url": "https://www.pharmaceutical-technology.com/news/vertex-agreement-to-buy-crinetics/", "source_name": "Pharmaceutical Technology", "published_at": "2026-07-07T10:13:56", "published_display": "07 Jul 2026 10:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)", "summary": "Brodsky & Smith is investigating potential claims against the Board of Directors of Crinetics Pharmaceuticals, Inc. (CRNX) following its sale to Vertex Pharmaceuticals Incorporated for $85.00 per share. The investigation focuses on whether the Crinetics Pharmaceuticals Board brea", "url": "https://www.newsfilecorp.com/release/304234/SHAREHOLDER-NOTICE-Brodsky-Smith-Announces-an-Investigation-of-Crinetics-Pharmaceuticals-Inc.-CRNX", "source_name": "TMX Newsfile", "published_at": "2026-07-07T09:28:00", "published_display": "07 Jul 2026 09:28", "sentiment": "negative", "sentiment_pct": 37, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOMTNHamtrLTQwWGVmMlRXa3F6LWc1bjZZd21mdk44M0NGSTRhWjE5UzZpbk95N0d2N2wyZjZXOGJZQjFUTWhnMWtYaERRTlYyNGJYdThoWjQzMC1EQzBRQjg3ZUxOcjBTQ1B3YVdzSl9BcGdPVjRrN0hoSDVRSmViakZOWE9qWVFPY3pjRlVxdDJnMlBLSzY2aVBR?oc=5", "source_name": "Fierce Pharma", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQZ3IwMUlZd3prNXBXLVloTG5vTnRObXJUXzVQRDg5SHZnMlRJZWV3amprMHYtRmJNUWJRQXo2RkVHc2RjMGxoRFR6b2tlYmowSlRlbklEVm5XYlVGZjByZXRFNmgyWjR3blUzRVVqSEF3XzlxTUhfN0xEc3VQbFVLT213MngxY0YwOUxtXzNLNDRqa0Iz?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics (CRNX) Stock Could Be Overvalued After Its 113% Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZGREMGQyYkpzRDNpVTItb3ZUMDV0TGMtcExzN0Q5NWR5a2pqX0FRcDM0dkM4XzdMcTF1OGltOUVMZTNfQlRsVWNLZ01CalNkNHlYQVdsSUFaLW5aMTktOUlLdUdKeDdKazIyZXdtT0ltVV9ZT2tPd3lZbzEzaHlLc0FvcFFid2xfRVN5YndiVXFKc0V1Q1lsRW9YMURFZE5LbDV1TA?oc=5", "source_name": "Market source", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPRHhJNWtVTS1YR3VDbUIzWjdrcW9TcVFXeWpGRTJsSmI0NVdWQmg3WExaM2Zsc19QSnh0Y1prNVdhT1BJa2FPTGtjSGdGdHVLVUVXYndrNTdiVG5ueTdqNDVhaWR3bzlVWFdpZVZXQU1nczVubzNCR0h4QWxDaWViSjZ6WGhSMHJXTkVZbHNmZTFLMmp6NDVpN29kbW9EaS1K?oc=5", "source_name": "Market source", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQU3l2VFZ2NzJQVFhMOTA3Slg4ZWt6aGt0bU1OWUVqOU9ES0doYmZzczd5azhvcGhrU1V6bGNyTzBfcy1pQmRlTnk3RUlvX1c3R24tbkJ6OW5SdGpjUDVmcVNtMnUwS2tTbEhkOVctVWYwLVBzYTFQMFdjY2x6V3FvaWVqTGhTd1Ewc1V5MGlQZ3JTdmZTZkFZY1NpVQ?oc=5", "source_name": "Market source", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals to be Acquired by Vertex Pharmaceuticals in $10 Billion Deal", "summary": "Paul, Weiss is advising Crinetics Pharmaceuticals, Inc. on its $10 billion all-cash acquisition by Vertex Pharmaceuticals Incorporated. Vertex will acquire Crinetics for $85 per share. The transaction is expected to close in the third quarter of 2026, pending customary closing co", "url": "https://www.paulweiss.com/insights/client-news/crinetics-pharmaceuticals-to-be-acquired-by-vertex-pharmaceuticals-in-10-billion-deal", "source_name": "Paul, Weiss", "published_at": "2026-07-07T01:41:39", "published_display": "07 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex (Nasdaq: VRTX) to acquire Crinetics (CRNX) in $10B cash deal", "summary": "Vertex Pharmaceuticals announced it will acquire Crinetics Pharmaceuticals for $10 billion in an all-cash deal, paying $85.00 per share. The acquisition will add Crinetics' FDA-approved acromegaly drug PALSONIFY and late-stage asset atumelnant to Vertex's portfolio, with potentia", "url": "https://www.stocktitan.net/sec-filings/CRNX/8-k-crinetics-pharmaceuticals-inc-reports-material-event-95d8beefaf4e.html", "source_name": "Stock Titan", "published_at": "2026-07-07T01:10:23", "published_display": "07 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Grows Its Rare Disease Business With $10bn Crinetics Buy", "summary": "Vertex Pharmaceuticals is expanding its rare disease portfolio by acquiring Crinetics Pharmaceuticals for $10 billion. This acquisition adds a fifth business group, endocrine diseases, to Vertex's operations, following the recent US and EU approval of Crinetics' drug Palsonify fo", "url": "https://insights.citeline.com/scrip/business/deals/vertex-grows-its-rare-disease-business-with-10bn-crinetics-buy-NWLU4IRD5JDEHNSFSM574X6EVY/", "source_name": "Scrip", "published_at": "2026-07-07T00:22:23", "published_display": "07 Jul 2026 00:22", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders", "summary": "Ademi LLP is investigating Crinetics Pharmaceuticals (Nasdaq: CRNX) regarding potential breaches of fiduciary duty due to its recently announced transaction with Vertex. Shareholders are set to receive $85.00 per share in cash, totaling approximately $10.0 billion, and Ademi LLP ", "url": "https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-crinetics-pharmaceuticals-inc-is-obtaining-a-fair-price-for-public-shareholders-302818811.html", "source_name": "PR Newswire", "published_at": "2026-07-07T00:10:22", "published_display": "07 Jul 2026 00:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex to acquire Crinetics for $10 billion in cash deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPTldzOTBYSmlkR1FSVVhDWFJmcDV1enZtM0VYaHJneVBZcGtXNFBUWDJUd092eEx5OWF2V0tRUUZQcXVvZGhLR0JXVDdMZmcxMmV4QW1kQ19oOWNVWWVGTHRCZ0IxRTdZZDJSeTBkczQ5bU5jMldqMEVWdWJvUVlqSFJxRFFqMUtsVFltNmwxeVhlT0E0Q2NEV00wUFNZdTZ0YkRERzRkY2R6TDlrTHRaUnZfc2tyUC11bFJLUXlLNUxTejN4SHJv?oc=5", "source_name": "Investing.com UK", "published_at": "2026-07-06T22:24:42+00:00", "published_display": "06 Jul 2026 22:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRNX Stock Soars Nearly 100% After-Hours On Vertex's $10B Acquisition", "summary": "Shares of Crinetics Pharmaceuticals (CRNX) surged nearly 100% in after-hours trading after Vertex Pharmaceuticals (VRTX) announced its intention to acquire the company for approximately $10 billion. The acquisition, valuing Crinetics at $85 per share in cash, aims to strengthen V", "url": "https://finance.yahoo.com/markets/stocks/articles/crnx-stock-soars-nearly-100-000712062.html", "source_name": "Market source", "published_at": "2026-07-06T23:13:56", "published_display": "06 Jul 2026 23:13", "sentiment": "positive", "sentiment_pct": 92, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex to buy Crinetics for $10 billion in rare-diseases push", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOX3N1NDFzcDNMSmVSODY1SEJGRm51Sl96QmtwWV9zMHA3RUZTRVlDenhJaG01alZQSU5KZUNWV2NFMFp6c0U5Xy1aZFZ2UXVmNWFGNk1HR1NMcGpJWHVpQjVtQWV2Z0FqMldWWHFwMlA2cHh1eDBtT19sem9BZ1ljblQta09WbWdBcjFzX3JVY2h2WlFsQ1VZ?oc=5", "source_name": "Reuters", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex strikes $10B deal for Crinetics and its endocrine drug portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQRjlNUFgzdzNLZXg2dlllYnVNa0RsSjMweWFVUFZzWkxnblpzdmZuX3h5TWIyWTRLLUdlQ0lFQl9JM21FNkFsLVp5RHJianJUTVlyUkZKSmZVSVNaTjFJbTVHWHZFZ0ZRSG1WRm5vUlFDeGt5U1MtTVNfMzdYakp4S21aOFdHbEVva2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Crinetics Pharmaceuticals (CRNX)", "summary": "This article analyzes the historical performance of Crinetics Pharmaceuticals (CRNX) stock, detailing how a $1,000 investment would have grown over 1, 5, and since 2018. It provides a comprehensive overview of the company's focus on endocrine diseases, its FDA-approved drug PALSO", "url": "https://www.stocktitan.net/tools/stock-return-calculator/CRNX", "source_name": "Stock Titan", "published_at": "2026-07-04T01:09:09", "published_display": "04 Jul 2026 01:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals Shares Rise After UBS Initiates Coverage", "summary": "Crinetics Pharmaceuticals (CRNX) saw its shares increase by over 6% after UBS initiated coverage with a \"Buy\" rating. The analyst set a price target of $70.00, suggesting significant upside potential for the stock. This positive analyst action reflects growing confidence in the c", "url": "https://www.moomoo.com/news/post/72414035/crinetics-pharmaceuticals-shares-rise-after-ubs-initiates-coverage?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-03T12:11:03", "published_display": "03 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals (CRNX) Receives Buy Rating from UBS with $55 Target GuruFocus News", "summary": "Crinetics Pharmaceuticals (CRNX) received a Buy rating from UBS with a $55 price target, despite a recent stock decline, due to anticipated success of its drug atumelnant and its flagship product, Palsonify. However, the company faces challenges including a low GF Score of 47/100", "url": "https://www.gurufocus.com/news/8943418/crinetics-pharmaceuticals-crnx-receives-buy-rating-from-ubs-with-55-target?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-03T01:39:19", "published_display": "03 Jul 2026 01:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS initiates Crinetics stock with buy rating, $55 price target", "summary": "UBS has initiated coverage on Crinetics Pharmaceuticals Inc. (CRNX) with a buy rating and a price target of $55, citing potential upside from its current price of $38.68. The firm projects risk-adjusted peak sales of $2.0 billion for the company\u2019s Phase 3 atumelnant in Congenital", "url": "https://www.investing.com/news/analyst-ratings/ubs-initiates-crinetics-stock-with-buy-rating-55-price-target-93CH-4772510", "source_name": "Investing.com", "published_at": "2026-07-02T23:41:04", "published_display": "02 Jul 2026 23:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jeff Knight to sell 44,925 shares at CRNX (NASDAQ: CRNX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQd0F1blN4MjN5T3I5VnNuN0dxMFZ6Z2dyVWVvbktPU1lJeHU5dmNENko2ck9Cc2RTZkw3MFZLTktqRVFrbDBtdnNBQ0laZWF0Rl9jSXdnTTVxZGpjdG9haHFWZ0VsZ0VMYjNhRzcyTWVULUE3UlhHU25BeWt0eVBZUlNOemFNSTNOaDVlbHVpeHAzOE9oQzcySExoelJlSUNNWFcwdW5sY2t1UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T20:34:11+00:00", "published_display": "02 Jul 2026 20:34", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Crinetics Pharmaceuticals, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQbHhub3dYbzJORGVJVlFCb051TGtPT3ZjNDBsQjFBTWM2clRrdjBIaFlLSGxiVTVwTU1wUkVpYWJsVTEwZXJtVDhrZlZycjJESUNUM1BEWHNNcExNYlVibjBxUmhEaXhEMGp6LUQxSG5laU01ZmRUR0FjZW45NGlHMEw1TUdyV2JVTG5yUnkzdzhwcUpZMXN1LWRlMGh3S0tKSWZyZDVnYmNzZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T20:29:53+00:00", "published_display": "02 Jul 2026 20:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Crinetics Pharmaceuticals For: 2 July By Investing.com", "summary": "This article from Investing.com reports on a Form 144 filing for Crinetics Pharmaceuticals (CRNX) on July 2. The filing is a regulatory notice indicating the intent to sell restricted securities. The article includes the stock symbol and notes a 9.18% increase for CRNX.", "url": "https://ca.investing.com/news/stock-market-news/form-144-crinetics-pharmaceuticals-for-2-july-93CH-4719033", "source_name": "Investing.com Canada", "published_at": "2026-07-02T21:10:43", "published_display": "02 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Crinetics Pharmaceuticals, Inc. (CRNX) Stock Positioned for Growth After Promising Atumelnant Clinical Results?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNRFI4TWVhSzlYc0ZrZkQ2MHplUHd2SDhNbWJHSl9ycVdwcFdLVDNWRTRPSUFyNjVJYWh3MnhFVlBGNFlady01aGlqVW0wV3h3Q2lvX3VFd2ViZ29ZRENyZTR3OXE4cG9mRS1pb0xrYllLMUtHbC15OHhCakpLU1NGZGg5QU1PSzN1YWFwck5rSUhYWk94QjRtcVpVbW5hMmdsS0FZ?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals: 'Buy' On Palsonify Market Expansion And Atumelnant Advancements", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNWUZZd2otSGJmQzZlem4ydFNicm9MaXNhcmRtUlRoR1NwbkZiSzJwam5ROWVSZ3kyNkVOUnhhMzNaY1lxNVFJYmJVSDFPWkxYM19oUFRZQWZ5Yi1LM1ltNWo0YU8wTUJQbFpwQ1gwSjNrTHo2S05LeDlsSnpTZ0hETk5ZamlGM1duTDJFN29HRV91dWhRNU5TZjN5QWYzbEkzOWoxWE4zd2NQWTNITHFNMkF5ck1WYkpUWmM3M2M0NEJxOG8?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNc1pxd2JOTkxfeW8tMS1IdF9ZOGNaX1pZV0NxaEhxLVVmVU1JbW5pcGZ2WExaUEdZSkFvQ2JBYTFZcWtnaDNpUzE2NU5aeEhUSnphdUhXQk02MFlrbE9ROXNrY3RTbGtITzFLMGc3UEtYQ0wzUWZySGd3M0NGeWc3dnotN2haQTdEZWJsQUx6cFBKeVVTZFhsaldFM1VDUjYwUF84VjFNV05SXzNM?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOaEVvZDdpdWhwVG9vZncwRFpTdGdqWDYybXRVeGYyWGw2Y0tibEluQVZ1RlJ0VkJNRU5Hcl9uNV9tV0hDLXBOcVlVOVNWVVZaT1FlWmw0RzJNalpZTzJPOUFoZVpIbDBqVHJiZEZmLUtmN2lJX3dyZGRBQWpYQXlaQ25BYllIQUp2NEFzNDBiRnYzYXEzMm90LXRyYndyZTJPVXBfaWprNzdGZw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "232 enrollment forms as Crinetics posts $10.3M Palsonify sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQU3cyZ3ZSYzlTRF82NlF3NksyRUVfbDhtaFlhMUNaYWV6b3BEU0lXT2pMVWxwNlFYTXUyQ1ZTdnNiNjBrazFtdmZUTDJlNEdSNXBRYVNpYkplZDI0ZmhXcjl6ZWNPM0ItTEZCMlhnRWZFZmh6dnQ2NHNIeUgxbkZRbEY4b25XbkxSUjg0bXRzMi14d2xySVp6OWplQU5HLS1fU2tnVjh4aGdiV3JfeGZBZWtHQzlYa1dI?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal", "summary": "Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals (CRNX) for $85 per share in an all-cash deal, valuing the acquisition at approximately $10 billion. The boards of both companies have unanimously approved the transaction, which is expected to close in Q3 of t", "url": "https://finance.yahoo.com/healthcare/articles/vertex-acquire-crinetics-pharmaceuticals-crnx-140143137.html", "source_name": "Market source", "published_at": "2026-07-15T21:01:00", "published_display": "15 Jul 2026 21:01", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex (VRTX) Is Buying Crinetics For $10 Billion To Enter Adrenal Disease", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T12:51:43+00:00", "published_display": "15 Jul 2026 12:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T10:59:35+00:00", "published_display": "15 Jul 2026 10:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals Acquired by Fortress Biotech for $10 Billion", "summary": "Fortress Biotech has acquired Crinetics Pharmaceuticals for approximately $10 billion, significantly enhancing its presence in the rare endocrine disease market. Crinetics' stock surged 99% on the news, despite facing profitability challenges and insider selling activity. The acq", "url": "https://news.biobuzz.io/news/crinetics-pharmaceuticals-acquired-by-fortress-biotech-for-10-billion/", "source_name": "BioBuzz", "published_at": "2026-07-15T03:40:34", "published_display": "15 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals stock hits all-time high at 83.77 USD", "summary": "Crinetics Pharmaceuticals Inc. (CRNX) stock has reached an all-time high of $83.77, reflecting a remarkable 163.21% increase over the past year. The company's market capitalization is now $8.83 billion, though InvestingPro analysis indicates it may be overvalued. This surge in st", "url": "https://www.investing.com/news/company-news/crinetics-pharmaceuticals-stock-hits-alltime-high-at-8377-usd-93CH-4791471", "source_name": "Investing.com", "published_at": "2026-07-14T18:18:52", "published_display": "14 Jul 2026 18:18", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals", "summary": "", "url": "https://finance.yahoo.com/m/26d3cf91-6ce0-39b4-a1c4-3cd3a89b796a/here%27s-why-vertex-was-willing.html", "source_name": "Motley Fool", "published_at": "2026-07-14T12:20:00+00:00", "published_display": "14 Jul 2026 12:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?", "summary": "", "url": "https://finance.yahoo.com/m/a6f71bfb-1081-3188-ab30-14417588df8b/does-vertex%27s-acquisition-of.html", "source_name": "Motley Fool", "published_at": "2026-07-13T18:47:07+00:00", "published_display": "13 Jul 2026 18:47", "sentiment": "positive", "sentiment_pct": 58, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist raises Vertex stock price target to $560 on Crinetics deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQakNJN1VzcnpMTjZnMjZpSWhwSlZibjZhbFZDLWpLTjBJdE5Jd01iVTkxdWQxRkhsejBqeU45QWZpWmpCQXVqcjluV0RjVlU0SVN0cl9wR2xVUVJQMXNkRDNzNkU2Yl9yX0dBaXROVWI4V012bkdXOEJtVVVtU1VRS0t5a3p2dHFBZllXcVJEbFo5LUtnVVNCTzZnZUhWTVNiak1RaVNyendzdXFLdTJzckVkYUZHdDh2Y1Faa21MdFNCbzltU1ZCdU02X1pRYnMySGpR?oc=5", "source_name": "Investing.com UK", "published_at": "2026-07-13T16:22:28+00:00", "published_display": "13 Jul 2026 16:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse", "summary": "", "url": "https://finance.yahoo.com/m/c948983b-0af9-31f4-9c90-8fb379aed97e/vertex-pharmaceuticals-bets.html", "source_name": "MarketBeat", "published_at": "2026-07-11T21:02:09+00:00", "published_display": "11 Jul 2026 21:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Crinetics Pharmaceuticals Inc. (CRNX) Affects Rotational Strategy Timing", "summary": "This article analyzes Crinetics Pharmaceuticals Inc. (CRNX) and its impact on rotational trading strategies, highlighting strong sentiment across all horizons. It provides AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-ti", "url": "https://news.stocktradersdaily.com/news_release/1/How_Crinetics_Pharmaceuticals_Inc._CRNX_Affects_Rotational_Strategy_Timing_071126021202_1783750322.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-11T02:12:00", "published_display": "11 Jul 2026 02:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals (CRNX) sets 1-year executive non-competes tied to Vertex deal", "summary": "Crinetics Pharmaceuticals has established one-year non-compete agreements with four key executives in connection with its upcoming merger with Vertex Pharmaceuticals. These agreements, effective post-merger, restrict the executives from working for competing businesses in Crineti", "url": "https://www.stocktitan.net/sec-filings/CRNX/8-k-crinetics-pharmaceuticals-inc-reports-material-event-338f33791120.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:09:14", "published_display": "10 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Vertex to Acquire Crinetics Pharmaceuticals", "summary": "Vertex Pharmaceuticals has announced its intention to acquire Crinetics Pharmaceuticals for approximately $4.8 billion. This acquisition will expand Vertex's pipeline, particularly with Crinetics' lead drug candidate, paltusotine, a somatostatin receptor type 2 (SST2) agonist for", "url": "https://www.moomoo.com/news/post/72542735/press-release-vertex-to-acquire-crinetics-pharmaceuticals", "source_name": "Moomoo", "published_at": "2026-07-10T04:10:22", "published_display": "10 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)", "summary": "Monteverde & Associates PC, a class action firm, has launched an investigation into Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) following its proposed acquisition by Vertex Pharmaceuticals Incorporated. The firm is examining whether the offered price of $85.00 per share in cas", "url": "https://www.prnewswire.com/news-releases/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-crinetics-pharmaceuticals-inc-nasdaq-crnx-302822146.html", "source_name": "PR Newswire", "published_at": "2026-07-10T02:09:14", "published_display": "10 Jul 2026 02:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Crinetics Pharmaceuticals Inc \u2013 DUS:6Z4", "summary": "This article from TradingView provides financial information for Crinetics Pharmaceuticals Inc (DUS:6Z4), specifically focusing on its price-to-book forward ratio. The content is primarily a listing of navigation and data sourcing information, indicating that detailed financial m", "url": "https://www.tradingview.com/symbols/DUS-6Z4/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T01:40:40", "published_display": "10 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Crinetics Stock Soared 99% This Week", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQRkJDNWFKa2JZdWRzTTY3bnNkYnRMLUdRUk5fdzJsQWktVjdhYUtwTUtTUHBaemVITlExMGJhOFBJdm84N2FHUW1NM2kyYktVLUR1UGZsNEc3c2FyZmRTaG9PNmVwY3pCYWM5RDQwcTEzSWZ1UmwycFZRbl85SnlZOUVxVDQxYUIzb090ZnV2YW5CdGtfSm9yQXhR?oc=5", "source_name": "Market source", "published_at": "2026-07-09T17:29:39+00:00", "published_display": "09 Jul 2026 17:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's How Much $1000 Invested In Crinetics Pharmaceuticals 5 Years Ago Would Be Worth Today", "summary": "Crinetics Pharmaceuticals (NASDAQ: CRNX) has significantly outperformed the market over the last five years, with an average annual return of 33.07%. A $1000 investment in CRNX stock five years ago would now be worth $4,029.44, demonstrating the substantial impact of compounded r", "url": "https://www.benzinga.com/news/26/07/60345730/here-s-how-much-1000-invested-crinetics-pharmaceuticals-5-years-ago-would-be-worth-today", "source_name": "Benzinga", "published_at": "2026-07-09T08:12:41", "published_display": "09 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex\u2019s Crinetics Deal Balances Growth with Integration Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQRFZNNjhfd3JXNzVPR0xJc2pqby13OTQ5Z1ktWms2YTJiaXNsdjNyUWkyaHVKcmFLbEZxUjh5OGNOZFRoLThxS2ZfWWp5c1B3YjFERGVRZUxkTkQweWJDTkxlMS15Y1FpcElpOXN5ZWRlVF8taFVBT3hRano2U1RYaGpsdlVJTnl2S1VrOTB3VGZNWmVvNXVpeGhmN2t6UQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-08T15:20:35+00:00", "published_display": "08 Jul 2026 15:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Crinetics Pharmaceuticals, Inc. (CRNX) Stock a Buying Opportunity After a 44% Pullback?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQWkJDMVF5SG13QURhc1dlWkJsR2c1c204ZFc0V21QRVlPSWJvQ2ZEOWhKSkZ6YjJ2SmVFUlBvQXMwcXdLQXQwaDctOXBXQm4xcDRpd0F3TVpvb2FQdkR6Y2Rna2lwS05mT1YzcXZvRU5Yd3UwR0tRbTVBSHdpdDFJQ1hEYW14aW5oYzBCcVF5a3VqTzJlemJMOEUyS3RfeFltdm1R?oc=5", "source_name": "Market source", "published_at": "2026-07-08T15:04:40+00:00", "published_display": "08 Jul 2026 15:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal", "summary": "Following Vertex Pharmaceuticals' $10 billion acquisition of Crinetics Pharmaceuticals, Viking Therapeutics (VKTX) has become a subject of renewed takeover speculation, particularly given its advancing obesity and metabolic disorder drug pipeline. The company's VK2735, in late-st", "url": "https://finance.yahoo.com/healthcare/articles/viking-therapeutics-vktx-draws-takeover-091235821.html", "source_name": "Market source", "published_at": "2026-07-08T05:12:00", "published_display": "08 Jul 2026 05:12", "sentiment": "positive", "sentiment_pct": 86, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly price target boost, Vertex-Crinetics deal, Meta's new social media lawsuit", "summary": "JPMorgan raised its price target for Eli Lilly (LLY) due to strong demand for Mounjaro and Zepbound, expecting over $20 billion in sales for the quarter. Vertex Pharmaceuticals (VRTX) is acquiring Crinetics (CRNX) for approximately $10 billion, a move that will likely expand Vert", "url": "https://finance.yahoo.com/video/eli-lilly-price-target-boost-vertex-crinetics-deal-metas-new-social-media-lawsuit-192844891.html", "source_name": "Market source", "published_at": "2026-07-07T19:13:53", "published_display": "07 Jul 2026 19:13", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals (CRNX) Agreed To A $10 Billion All Cash Sale To Vertex", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T16:40:26+00:00", "published_display": "07 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals Stock (CRNX) Opinions on Vertex Acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQZnZPRzNITk1wTEdHSFNUMVk5clU0VjdiemhZbVF3RTVBN3VzZW9PVmRyWlVsT3lBTHpZOTJGaE83bXdQR3pYU2FNM09TeGNhSjUteFUwcVlBVjNCa2RnNXduYm5lYXVvVUtySmlWeTh0V2FMRlJfdWF4aTNQVjYzREtZUGhfTE1oV01EazRMcWVjVm9VeHY0YmdxZDBnMmNMTkVkOHpoYW5VUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-07T14:06:00+00:00", "published_display": "07 Jul 2026 14:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex to Acquire Crinetics in $10 Billion Merger", "summary": "Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion in cash, or $85 per share. This acquisition, expected to close in Q3 2026, will integrate Crinetics' PALSONIFY acromegaly franchise and atumelnant CAH program into Vertex's portfolio, aiming fo", "url": "https://www.tipranks.com/news/company-announcements/vertex-to-acquire-crinetics-in-10-billion-merger", "source_name": "TipRanks", "published_at": "2026-07-07T14:12:41", "published_display": "07 Jul 2026 14:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex to Acquire Crinetics Pharmaceuticals", "summary": "Vertex Pharmaceuticals announced its intent to acquire Crinetics Pharmaceuticals for approximately $10.0 billion, or $8.8 billion net of cash acquired, at $85.00 per share in cash. The acquisition will add Crinetics' recently launched PALSONIFY\u00ae for acromegaly and its Phase 3 can", "url": "https://www.biospace.com/press-releases/vertex-to-acquire-crinetics-pharmaceuticals", "source_name": "BioSpace", "published_at": "2026-07-07T13:40:40", "published_display": "07 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 87, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know (NASDAQ:CRNX)", "summary": "Vertex Pharmaceuticals announced its intention to acquire Crinetics Pharmaceuticals for approximately $10 billion, paying $85 per share. This acquisition aims to diversify Vertex's portfolio beyond cystic fibrosis, adding Crinetics' newly approved acromegaly therapy PALSONIFY and", "url": "https://seekingalpha.com/article/4920310-vertex-to-acquire-crinetics-for-10bn-what-investors-should-know", "source_name": "Seeking Alpha", "published_at": "2026-07-07T13:13:53", "published_display": "07 Jul 2026 13:13", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex to acquire Crinetics in $10B foray into endocrine disease drugs", "summary": "Vertex Pharmaceuticals announced its largest acquisition to date, planning to buy Crinetics Pharmaceuticals for $10 billion (or $85 per share) to expand into endocrine disorder treatments. This strategic move aims to diversify Vertex's portfolio beyond its successful cystic fibro", "url": "https://www.biopharmadive.com/news/vertex-crinetics-acquire-deal-palsonify-acromegaly/824545/", "source_name": "BioPharma Dive", "published_at": "2026-07-07T13:13:53", "published_display": "07 Jul 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex signs agreement to acquire Crinetics for $10bn", "summary": "Vertex Pharmaceuticals has signed a definitive agreement to acquire Crinetics Pharmaceuticals for nearly $10 billion. This acquisition, expected to close in Q3 2026, will add two main endocrinology assets to Vertex's portfolio: Palsonify for acromegaly and atumelnant for congenit", "url": "https://www.pharmaceutical-technology.com/news/vertex-agreement-to-buy-crinetics/", "source_name": "Pharmaceutical Technology", "published_at": "2026-07-07T10:13:56", "published_display": "07 Jul 2026 10:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)", "summary": "Brodsky & Smith is investigating potential claims against the Board of Directors of Crinetics Pharmaceuticals, Inc. (CRNX) following its sale to Vertex Pharmaceuticals Incorporated for $85.00 per share. The investigation focuses on whether the Crinetics Pharmaceuticals Board brea", "url": "https://www.newsfilecorp.com/release/304234/SHAREHOLDER-NOTICE-Brodsky-Smith-Announces-an-Investigation-of-Crinetics-Pharmaceuticals-Inc.-CRNX", "source_name": "TMX Newsfile", "published_at": "2026-07-07T09:28:00", "published_display": "07 Jul 2026 09:28", "sentiment": "negative", "sentiment_pct": 37, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOMTNHamtrLTQwWGVmMlRXa3F6LWc1bjZZd21mdk44M0NGSTRhWjE5UzZpbk95N0d2N2wyZjZXOGJZQjFUTWhnMWtYaERRTlYyNGJYdThoWjQzMC1EQzBRQjg3ZUxOcjBTQ1B3YVdzSl9BcGdPVjRrN0hoSDVRSmViakZOWE9qWVFPY3pjRlVxdDJnMlBLSzY2aVBR?oc=5", "source_name": "Fierce Pharma", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQZ3IwMUlZd3prNXBXLVloTG5vTnRObXJUXzVQRDg5SHZnMlRJZWV3amprMHYtRmJNUWJRQXo2RkVHc2RjMGxoRFR6b2tlYmowSlRlbklEVm5XYlVGZjByZXRFNmgyWjR3blUzRVVqSEF3XzlxTUhfN0xEc3VQbFVLT213MngxY0YwOUxtXzNLNDRqa0Iz?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics (CRNX) Stock Could Be Overvalued After Its 113% Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZGREMGQyYkpzRDNpVTItb3ZUMDV0TGMtcExzN0Q5NWR5a2pqX0FRcDM0dkM4XzdMcTF1OGltOUVMZTNfQlRsVWNLZ01CalNkNHlYQVdsSUFaLW5aMTktOUlLdUdKeDdKazIyZXdtT0ltVV9ZT2tPd3lZbzEzaHlLc0FvcFFid2xfRVN5YndiVXFKc0V1Q1lsRW9YMURFZE5LbDV1TA?oc=5", "source_name": "Market source", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPRHhJNWtVTS1YR3VDbUIzWjdrcW9TcVFXeWpGRTJsSmI0NVdWQmg3WExaM2Zsc19QSnh0Y1prNVdhT1BJa2FPTGtjSGdGdHVLVUVXYndrNTdiVG5ueTdqNDVhaWR3bzlVWFdpZVZXQU1nczVubzNCR0h4QWxDaWViSjZ6WGhSMHJXTkVZbHNmZTFLMmp6NDVpN29kbW9EaS1K?oc=5", "source_name": "Market source", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQU3l2VFZ2NzJQVFhMOTA3Slg4ZWt6aGt0bU1OWUVqOU9ES0doYmZzczd5azhvcGhrU1V6bGNyTzBfcy1pQmRlTnk3RUlvX1c3R24tbkJ6OW5SdGpjUDVmcVNtMnUwS2tTbEhkOVctVWYwLVBzYTFQMFdjY2x6V3FvaWVqTGhTd1Ewc1V5MGlQZ3JTdmZTZkFZY1NpVQ?oc=5", "source_name": "Market source", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals to be Acquired by Vertex Pharmaceuticals in $10 Billion Deal", "summary": "Paul, Weiss is advising Crinetics Pharmaceuticals, Inc. on its $10 billion all-cash acquisition by Vertex Pharmaceuticals Incorporated. Vertex will acquire Crinetics for $85 per share. The transaction is expected to close in the third quarter of 2026, pending customary closing co", "url": "https://www.paulweiss.com/insights/client-news/crinetics-pharmaceuticals-to-be-acquired-by-vertex-pharmaceuticals-in-10-billion-deal", "source_name": "Paul, Weiss", "published_at": "2026-07-07T01:41:39", "published_display": "07 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex (Nasdaq: VRTX) to acquire Crinetics (CRNX) in $10B cash deal", "summary": "Vertex Pharmaceuticals announced it will acquire Crinetics Pharmaceuticals for $10 billion in an all-cash deal, paying $85.00 per share. The acquisition will add Crinetics' FDA-approved acromegaly drug PALSONIFY and late-stage asset atumelnant to Vertex's portfolio, with potentia", "url": "https://www.stocktitan.net/sec-filings/CRNX/8-k-crinetics-pharmaceuticals-inc-reports-material-event-95d8beefaf4e.html", "source_name": "Stock Titan", "published_at": "2026-07-07T01:10:23", "published_display": "07 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex Grows Its Rare Disease Business With $10bn Crinetics Buy", "summary": "Vertex Pharmaceuticals is expanding its rare disease portfolio by acquiring Crinetics Pharmaceuticals for $10 billion. This acquisition adds a fifth business group, endocrine diseases, to Vertex's operations, following the recent US and EU approval of Crinetics' drug Palsonify fo", "url": "https://insights.citeline.com/scrip/business/deals/vertex-grows-its-rare-disease-business-with-10bn-crinetics-buy-NWLU4IRD5JDEHNSFSM574X6EVY/", "source_name": "Scrip", "published_at": "2026-07-07T00:22:23", "published_display": "07 Jul 2026 00:22", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders", "summary": "Ademi LLP is investigating Crinetics Pharmaceuticals (Nasdaq: CRNX) regarding potential breaches of fiduciary duty due to its recently announced transaction with Vertex. Shareholders are set to receive $85.00 per share in cash, totaling approximately $10.0 billion, and Ademi LLP ", "url": "https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-crinetics-pharmaceuticals-inc-is-obtaining-a-fair-price-for-public-shareholders-302818811.html", "source_name": "PR Newswire", "published_at": "2026-07-07T00:10:22", "published_display": "07 Jul 2026 00:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex to acquire Crinetics for $10 billion in cash deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPTldzOTBYSmlkR1FSVVhDWFJmcDV1enZtM0VYaHJneVBZcGtXNFBUWDJUd092eEx5OWF2V0tRUUZQcXVvZGhLR0JXVDdMZmcxMmV4QW1kQ19oOWNVWWVGTHRCZ0IxRTdZZDJSeTBkczQ5bU5jMldqMEVWdWJvUVlqSFJxRFFqMUtsVFltNmwxeVhlT0E0Q2NEV00wUFNZdTZ0YkRERzRkY2R6TDlrTHRaUnZfc2tyUC11bFJLUXlLNUxTejN4SHJv?oc=5", "source_name": "Investing.com UK", "published_at": "2026-07-06T22:24:42+00:00", "published_display": "06 Jul 2026 22:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRNX Stock Soars Nearly 100% After-Hours On Vertex's $10B Acquisition", "summary": "Shares of Crinetics Pharmaceuticals (CRNX) surged nearly 100% in after-hours trading after Vertex Pharmaceuticals (VRTX) announced its intention to acquire the company for approximately $10 billion. The acquisition, valuing Crinetics at $85 per share in cash, aims to strengthen V", "url": "https://finance.yahoo.com/markets/stocks/articles/crnx-stock-soars-nearly-100-000712062.html", "source_name": "Market source", "published_at": "2026-07-06T23:13:56", "published_display": "06 Jul 2026 23:13", "sentiment": "positive", "sentiment_pct": 92, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex to buy Crinetics for $10 billion in rare-diseases push", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOX3N1NDFzcDNMSmVSODY1SEJGRm51Sl96QmtwWV9zMHA3RUZTRVlDenhJaG01alZQSU5KZUNWV2NFMFp6c0U5Xy1aZFZ2UXVmNWFGNk1HR1NMcGpJWHVpQjVtQWV2Z0FqMldWWHFwMlA2cHh1eDBtT19sem9BZ1ljblQta09WbWdBcjFzX3JVY2h2WlFsQ1VZ?oc=5", "source_name": "Reuters", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vertex strikes $10B deal for Crinetics and its endocrine drug portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQRjlNUFgzdzNLZXg2dlllYnVNa0RsSjMweWFVUFZzWkxnblpzdmZuX3h5TWIyWTRLLUdlQ0lFQl9JM21FNkFsLVp5RHJianJUTVlyUkZKSmZVSVNaTjFJbTVHWHZFZ0ZRSG1WRm5vUlFDeGt5U1MtTVNfMzdYakp4S21aOFdHbEVva2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Crinetics Pharmaceuticals (CRNX)", "summary": "This article analyzes the historical performance of Crinetics Pharmaceuticals (CRNX) stock, detailing how a $1,000 investment would have grown over 1, 5, and since 2018. It provides a comprehensive overview of the company's focus on endocrine diseases, its FDA-approved drug PALSO", "url": "https://www.stocktitan.net/tools/stock-return-calculator/CRNX", "source_name": "Stock Titan", "published_at": "2026-07-04T01:09:09", "published_display": "04 Jul 2026 01:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals Shares Rise After UBS Initiates Coverage", "summary": "Crinetics Pharmaceuticals (CRNX) saw its shares increase by over 6% after UBS initiated coverage with a \"Buy\" rating. The analyst set a price target of $70.00, suggesting significant upside potential for the stock. This positive analyst action reflects growing confidence in the c", "url": "https://www.moomoo.com/news/post/72414035/crinetics-pharmaceuticals-shares-rise-after-ubs-initiates-coverage?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-03T12:11:03", "published_display": "03 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals (CRNX) Receives Buy Rating from UBS with $55 Target GuruFocus News", "summary": "Crinetics Pharmaceuticals (CRNX) received a Buy rating from UBS with a $55 price target, despite a recent stock decline, due to anticipated success of its drug atumelnant and its flagship product, Palsonify. However, the company faces challenges including a low GF Score of 47/100", "url": "https://www.gurufocus.com/news/8943418/crinetics-pharmaceuticals-crnx-receives-buy-rating-from-ubs-with-55-target?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-03T01:39:19", "published_display": "03 Jul 2026 01:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS initiates Crinetics stock with buy rating, $55 price target", "summary": "UBS has initiated coverage on Crinetics Pharmaceuticals Inc. (CRNX) with a buy rating and a price target of $55, citing potential upside from its current price of $38.68. The firm projects risk-adjusted peak sales of $2.0 billion for the company\u2019s Phase 3 atumelnant in Congenital", "url": "https://www.investing.com/news/analyst-ratings/ubs-initiates-crinetics-stock-with-buy-rating-55-price-target-93CH-4772510", "source_name": "Investing.com", "published_at": "2026-07-02T23:41:04", "published_display": "02 Jul 2026 23:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jeff Knight to sell 44,925 shares at CRNX (NASDAQ: CRNX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQd0F1blN4MjN5T3I5VnNuN0dxMFZ6Z2dyVWVvbktPU1lJeHU5dmNENko2ck9Cc2RTZkw3MFZLTktqRVFrbDBtdnNBQ0laZWF0Rl9jSXdnTTVxZGpjdG9haHFWZ0VsZ0VMYjNhRzcyTWVULUE3UlhHU25BeWt0eVBZUlNOemFNSTNOaDVlbHVpeHAzOE9oQzcySExoelJlSUNNWFcwdW5sY2t1UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T20:34:11+00:00", "published_display": "02 Jul 2026 20:34", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Crinetics Pharmaceuticals, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQbHhub3dYbzJORGVJVlFCb051TGtPT3ZjNDBsQjFBTWM2clRrdjBIaFlLSGxiVTVwTU1wUkVpYWJsVTEwZXJtVDhrZlZycjJESUNUM1BEWHNNcExNYlVibjBxUmhEaXhEMGp6LUQxSG5laU01ZmRUR0FjZW45NGlHMEw1TUdyV2JVTG5yUnkzdzhwcUpZMXN1LWRlMGh3S0tKSWZyZDVnYmNzZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T20:29:53+00:00", "published_display": "02 Jul 2026 20:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Crinetics Pharmaceuticals For: 2 July By Investing.com", "summary": "This article from Investing.com reports on a Form 144 filing for Crinetics Pharmaceuticals (CRNX) on July 2. The filing is a regulatory notice indicating the intent to sell restricted securities. The article includes the stock symbol and notes a 9.18% increase for CRNX.", "url": "https://ca.investing.com/news/stock-market-news/form-144-crinetics-pharmaceuticals-for-2-july-93CH-4719033", "source_name": "Investing.com Canada", "published_at": "2026-07-02T21:10:43", "published_display": "02 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Crinetics Pharmaceuticals, Inc. (CRNX) Stock Positioned for Growth After Promising Atumelnant Clinical Results?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNRFI4TWVhSzlYc0ZrZkQ2MHplUHd2SDhNbWJHSl9ycVdwcFdLVDNWRTRPSUFyNjVJYWh3MnhFVlBGNFlady01aGlqVW0wV3h3Q2lvX3VFd2ViZ29ZRENyZTR3OXE4cG9mRS1pb0xrYllLMUtHbC15OHhCakpLU1NGZGg5QU1PSzN1YWFwck5rSUhYWk94QjRtcVpVbW5hMmdsS0FZ?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals: 'Buy' On Palsonify Market Expansion And Atumelnant Advancements", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNWUZZd2otSGJmQzZlem4ydFNicm9MaXNhcmRtUlRoR1NwbkZiSzJwam5ROWVSZ3kyNkVOUnhhMzNaY1lxNVFJYmJVSDFPWkxYM19oUFRZQWZ5Yi1LM1ltNWo0YU8wTUJQbFpwQ1gwSjNrTHo2S05LeDlsSnpTZ0hETk5ZamlGM1duTDJFN29HRV91dWhRNU5TZjN5QWYzbEkzOWoxWE4zd2NQWTNITHFNMkF5ck1WYkpUWmM3M2M0NEJxOG8?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNc1pxd2JOTkxfeW8tMS1IdF9ZOGNaX1pZV0NxaEhxLVVmVU1JbW5pcGZ2WExaUEdZSkFvQ2JBYTFZcWtnaDNpUzE2NU5aeEhUSnphdUhXQk02MFlrbE9ROXNrY3RTbGtITzFLMGc3UEtYQ0wzUWZySGd3M0NGeWc3dnotN2haQTdEZWJsQUx6cFBKeVVTZFhsaldFM1VDUjYwUF84VjFNV05SXzNM?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOaEVvZDdpdWhwVG9vZncwRFpTdGdqWDYybXRVeGYyWGw2Y0tibEluQVZ1RlJ0VkJNRU5Hcl9uNV9tV0hDLXBOcVlVOVNWVVZaT1FlWmw0RzJNalpZTzJPOUFoZVpIbDBqVHJiZEZmLUtmN2lJX3dyZGRBQWpYQXlaQ25BYllIQUp2NEFzNDBiRnYzYXEzMm90LXRyYndyZTJPVXBfaWprNzdGZw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "232 enrollment forms as Crinetics posts $10.3M Palsonify sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQU3cyZ3ZSYzlTRF82NlF3NksyRUVfbDhtaFlhMUNaYWV6b3BEU0lXT2pMVWxwNlFYTXUyQ1ZTdnNiNjBrazFtdmZUTDJlNEdSNXBRYVNpYkplZDI0ZmhXcjl6ZWNPM0ItTEZCMlhnRWZFZmh6dnQ2NHNIeUgxbkZRbEY4b25XbkxSUjg0bXRzMi14d2xySVp6OWplQU5HLS1fU2tnVjh4aGdiV3JfeGZBZWtHQzlYa1dI?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 108, "total_relevant": 65, "sentiment_summary": {"positive": 25, "negative": 5, "neutral": 35, "score": 60, "total": 65, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 73, "events": [{"event": "general", "label": "Market update", "weight": 12.8, "count": 22}, {"event": "deals", "label": "Deals and strategy", "weight": 12.45, "count": 22}, {"event": "earnings", "label": "Earnings", "weight": 5.36, "count": 12}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 25, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 83.58, "latest_week": "2026-07-10", "one_week_move": 97.9, "four_week_move": 142.5, "twelve_week_move": 103.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.746428, "market_dynamics_buy_signal": false, "relative_strength": 76.217726, "fair_value_gap": 109.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.1037, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+97.9% over one week, +142.5% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 15}, {"label": "Stock Titan", "count": 7}, {"label": "simplywall.st", "count": 6}, {"label": "Investing.com", "count": 2}, {"label": "Motley Fool", "count": 2}, {"label": "Investing.com UK", "count": 2}, {"label": "MarketBeat", "count": 2}, {"label": "Moomoo", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Deals and strategy", "count": 22}, {"label": "Market update", "count": 22}, {"label": "Earnings", "count": 12}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 3}, {"label": "Balance sheet", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "73/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+97.9% over one week, +142.5% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal"}], "updated_at": "2026-07-17T06:05:50.641348+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}